Literature DB >> 9165266

GM allotypes and IgG subclass concentrations in blacks.

J P Pandey1, J C Gunsolley, J G Tew, H A Schenkein.   

Abstract

IgG subclass concentrations were measured in 352 black Americans. Sera were also typed for nine GM allotypes. Serum concentrations of IgG1, IgG3, and IgG4 varied, to different degrees, according to GM phenotypes. The concentration of IgG1 was lower in subjects with GM 1,3,17 5,6,13 compared to those who lacked this phenotype. Elevated levels of IgG3 and IgG4 were associated with GM 1,17 5,6,13 and GM 1,3,17 23 5,13, respectively. Subjects with GM 1,17 5,13,21 had lower levels of IgG3 than individuals with other phenotypes. IgG2 levels were not associated with any of the GM phenotypes. To our knowledge, this represents the first report of an association between GM allotypes and IgG subclasses in blacks.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9165266

Source DB:  PubMed          Journal:  Exp Clin Immunogenet        ISSN: 0254-9670


  4 in total

1.  Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus.

Authors:  Janardan P Pandey; Jacquie Astemborski; David L Thomas
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies.

Authors:  Terrance P O'Hanlon; Lisa G Rider; Adam Schiffenbauer; Ira N Targoff; Karen Malley; Janardan P Pandey; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2008-10

3.  Antigen-specific influence of GM/KM allotypes on IgG isotypes and association of GM allotypes with susceptibility to Plasmodium falciparum malaria.

Authors:  Hayder A Giha; Amre Nasr; Nnaemeka C Iriemenam; David Arnot; Marita Troye-Blomberg; Thor G Theander; Klavs Berzins; Gehad ElGhazali; Janardan P Pandey
Journal:  Malar J       Date:  2009-12-22       Impact factor: 2.979

4.  Immunoglobulin GM and KM genes and measles vaccine-induced humoral immunity.

Authors:  Inna G Ovsyannikova; Beth R Larrabee; Daniel J Schaid; Gregory A Poland
Journal:  Vaccine       Date:  2017-03-06       Impact factor: 4.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.